The Anttis have produced a company report on Nightingale inspired by the recent news 
Nightingale has announced two new mid-sized proteomics service agreements in October. In addition, the company has reported a public healthcare pilot in Finland and a new clinical partnership in the UK. Based on these agreements, we are raising our revenue and earnings forecasts for the coming years. We reiterate our Accumulate recommendation and raise our target price to EUR 1.60 (prev. EUR 1.30) following the forecast revisions and improved visibility.